Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel
Authors:
- Barbara PratscherBPBarbara Pratscher
- Jürgen SoutschekJSJürgen Soutschek
- Anke GeickAGAnke Geick
- Hans-Peter VornlocherHVHans-Peter Vornlocher
- Markus MüllerMMMarkus Müller
- Volker WacheckVWVolker Wacheck
- 1 August 2007
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 18 (7) , 755-761
Abstract
The antiapoptotic protein Bcl-2 contributes to a more chemoresistant phenotype of nonsmall cell lung cancer and therefore serves as an important target for novel anticancer strategies. Interestingly, docetaxel as a standard of care for treatment of nonsmall cell lung cancer has been shown to inactivate the Bcl-2 function by phosphorylation. We investigated the Bcl-2 expression status of nonsmall cell lung cancer cells in response to cisplatin or docetaxel and its effect on sensitizing nonsmall cell lung cancer cells by Bcl-2 downregulation employing a small interfering RNA approach. Bcl-2 expression was assessed by Western blotting and RT-PCR. Cell proliferation and apoptosis of nonsmall cell lung cancer cells were measured by an MTS-based assay and Annexin V/7-Aminoactinomycin, respectively. Combination treatment of Bcl-2 small interfering RNA with cisplatin resulted in a synergistic activity. By contrast, Bcl-2 downregulation did not sensitize nonsmall cell lung cancer cells to docetaxel. Of note, docetaxel treatment resulted in Bcl-2 phosphorylation of nonsmall cell lung cancer cells, whereas cisplatin increased the Bcl-2 overall expression and abrogated Bcl-2 phosphorylation. On the basis of our findings, a Bcl-2 silencing approach appears to be a suitable strategy for sensitizing nonsmall cell lung cancer to cisplatin, but not to docetaxel.Keywords
This publication has 27 references indexed in Scilit:
- Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung CancerChest, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Role of Adjuvant Chemotherapy in Patients With Resected Non–Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled TrialsJournal of Clinical Oncology, 2004
- Postoperative chemotherapy for non–small cell lung cancer: A systematic review and meta-analysisThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide)Clinical Cancer Research, 2004
- Prognostic value of immunohistochemical expression of p53, bax, Bcl‐2 and Bcl‐xL in resected non‐small‐cell lung cancersHistopathology, 2004
- The Bcl-2 family: roles in cell survival and oncogenesisOncogene, 2003
- The role of the Bcl-2 protein family in cancerSeminars in Cancer Biology, 2003
- Apoptosis-targeted therapies for cancerCancer Cell, 2003
- The Bcl2 family: regulators of the cellular life-or-death switchNature Reviews Cancer, 2002